Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron by MASON, Jay W, SELNESS, Daniel S, MOON, Thomas E, O'MAHONY, Bridget, DONACHIE, Peter, HOWELL, Julian

Get full text

Pharmacokinetics and Pharmacodynamics of Three Moxifloxacin Dosage Forms: Implications for Blinding in Active-Controlled Cardiac Repolarization Studies by Mason, Jay W., Florian Jr, Jeffry A., Garnett, Christine E., Moon, Thomas E., Selness, Daniel S., Spaulding, Randol R.

Get full text

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results by Genge, Angela, Pattee, Gary L., Sobue, Gen, Couratier, Philippe, Selness, Daniel, Bidani, Sachin, Hirai, Manabu, Salah, Alejandro, Apple, Stephen

Get full text

Phase 3B study evaluating superiority of daily dosing vs approved on/off oral edaravone dosing over 48 weeks in patients with amyotrophic lateral sclerosis (MT-1186-A02) by Salah, Alejandro, Desilva, Shari, Zinman, Lorne, Chum, Marvin, Chio, Adriano, Ludolph, Albert C., Sobue, Gen, Doyu, Manabu, Selness, Daniel, Todorovic, Vesna, Hirai, Manabu, Wamil, Art, Apple, Stephen

Get full text

Phase 3B extension study evaluating superiority of daily vs approved on/off oral edaravone dosing in patients with amyotrophic lateral sclerosis by Rothstein, Jeffrey, Desilva, Shari, Zinman, Lorne, Chum, Marvin, Chio, Adriano, Ludolph, Albert C., Sobue, Gen, Doyu, Manabu, Selness, Daniel, Todorovic, Vesna, Hirai, Manabu, Fumihiro, Takahashi, Wamil, Art, Salah, Alejandro, Apple, Stephen

Get full text

Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers by Dutta, Sandeep, Zhang, Yiming, Selness, Daniel S., Lee, Lillian L., Williams, Laura A., Sommerville, Kenneth W.

Get full text

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment by Genge, Angela, Pattee, Gary L., Sobue, Gen, Aoki, Masashi, Yoshino, Hiide, Couratier, Philippe, Lunetta, Christian, Petri, Susanne, Selness, Daniel, Bidani, Sachin, Hirai, Manabu, Sakata, Takeshi, Salah, Alejandro, Apple, Stephen, Wamil, Art, Kalin, Alexander, Jackson, Carlayne E.

Get full text

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48weeks of treatment by Genge, Angela, Pattee, Gary L, Sobue, Gen, Aoki, Masashi, Yoshino, Hiide, Couratier, Philippe, Lunetta, Christian, Petri, Susanne, Selness, Daniel, Bidani, Sachin, Hirai, Manabu, Sakata, Takeshi, Salah, Alejandro, Apple, Stephen, Wamil, Art, Kalin, Alexander, Jackson, Carlayne E

Get full text

Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning by Schnute, Mark E, Benoit, Stephen E, Buchler, Ingrid P, Caspers, Nicole, Grapperhaus, Margaret L, Han, Seungil, Hotchandani, Rajeev, Huang, Nelson, Hughes, Robert O, Juba, Brian M, Kim, Kyung-Hee, Liu, Erica, McCarthy, Erin, Messing, Dean, Miyashiro, Joy S, Mohan, Shashi, O’Connell, Thomas N, Ohren, Jeffrey F, Parikh, Mihir D, Schmidt, Michelle, Selness, Shaun R, Springer, John R, Thanabal, Venkataraman, Trujillo, John I, Walker, Daniel P, Wan, Zhao-Kui, Withka, Jane M, Wittwer, Arthur J, Wood, Nancy L, Xing, Li, Zapf, Christoph W, Douhan, John

Get full text

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase by Walker, John K., Selness, Shaun R., Devraj, Rajesh V., Hepperle, Michael E., Naing, Win, Shieh, Huey, Kurambail, Ravi, Yang, Syaulan, Flynn, Daniel L., Benson, Alan G., Messing, Dean M., Dice, Tom, Kim, Tina, Lindmark, R.J., Monahan, Joseph B., Portanova, Joseph

Get full text